|Bid||46.00 x 800|
|Ask||47.80 x 800|
|Day's Range||46.70 - 50.38|
|52 Week Range||30.79 - 59.89|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 27, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.20|
Roche Holding AG said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. It's the second drug to be approved by the regulator to treat the rare disease. The therapy was developed by PTC Therapeutics Inc. and will be marketed by Genentech, a division of Roche. "We believe Evrysdi, with its favorable clinical profile and oral administration, may offer meaningful benefits for many living with this rare neurological disease," Roche's Levi Garraway said in a news release. A spokesperson said in an email that the treatment will cost about $340,000 per year, which is a lower price point than Biogen's Spinraza and AveXis Inc.'s Zolgensma; however the lower-than-expected price "could help increase market share and rapidity of adoption, though will produce lower revenue per patient than we had estimated," RBC Capital Markets' Brian Abrahams wrote in a note to investors. Since the start of the year, PTC's stock is down 0.4%, shares of Roche have gained 6.2%, and the S&P 500 is up 3.7%.
PTC Therapeutics, Inc.'s (NASDAQ:PTCT): PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older. Evrysdi showed clinically meaningful improvements in motor function and obtainment of developmental milestones across two trials in patients age two months and above and across all levels of disease severity, including types 1, 2, and 3 SMA. Infants achieved key motor milestones not normally seen in the natural course of the disease, such as the ability to sit without support. Evrysdi also preserved vital functions and improved survival at 12 months. In particular, Evrysdi improved survival without permanent ventilation compared to natural history when measured at 12 and 23 months.